Daily Endocrinology Research Analysis
Analyzed 29 papers and selected 3 impactful papers.
Summary
Analyzed 29 papers and selected 3 impactful articles.
Selected Articles
1. Agreement Between Molecular Imaging and Adrenal Vein Sampling for Localization in Primary Aldosteronism: A Systematic Review.
Across 20 studies, molecular imaging demonstrated moderate agreement with adrenal vein sampling for lateralization in primary aldosteronism (positive percent agreement 0.6–0.9; negative percent agreement 0.5–0.9; κ 0.33–0.93). Due to tracer heterogeneity, pooling was not feasible, supporting a complementary role for molecular imaging within diagnostic algorithms pending outcome-based validation.
Impact: This review synthesizes head-to-head evidence on a noninvasive alternative to AVS, a bottleneck in primary aldosteronism care, potentially reshaping diagnostic pathways.
Clinical Implications: Molecular imaging can be considered as an adjunct or alternative when AVS is infeasible or inconclusive, particularly in centers with tracer expertise, while recognizing the need for outcome-driven validation.
Key Findings
- Positive percent agreement between molecular imaging and AVS ranged 0.6–0.9; negative percent agreement 0.5–0.9.
- Cohen’s κ ranged 0.33–0.93, indicating moderate-to-strong agreement beyond chance.
- Heterogeneity in tracers and protocols precluded quantitative pooling; analyses were tracer-specific.
- Reciprocal analyses showed no consistent directional bias favoring either modality.
Methodological Strengths
- Systematic head-to-head comparison against prespecified AVS criteria
- Use of multiple agreement metrics (PPA, NPA, Cohen’s κ) and reciprocal sensitivity analyses
Limitations
- Substantial heterogeneity in tracers, preparation, and interpretation precluded meta-analytic pooling
- Lack of patient outcome-based validation limits clinical decisiveness
Future Directions: Prospective, outcome-based comparative effectiveness trials and standardization of tracer protocols and interpretation are needed to define when molecular imaging can replace AVS.
BACKGROUND: Primary aldosteronism is a common cause of hypertension that is curable via surgery when localized to a single adrenal gland. Localization testing has traditionally relied upon adrenal vein sampling (AVS); however, molecular imaging has emerged as a promising noninvasive alternative. METHODS: We performed a systematic synthesis of studies comparing molecular imaging with AVS for localization in primary aldosteronism. Studies directly comparing both modalities with prespecified AVS localization criteria were eligible. Agreement was evaluated using positive percent agreement, negative percent agreement, and, where available, Cohen's κ. Because molecular imaging tracers differ in biological targets and interpretation criteria, agreement metrics were examined by tracer rather than pooled. Sensitivity analyses repeated positive percent agreement and negative percent agreement calculations using molecular imaging as the reference. RESULTS: Twenty studies were included. Across tracers, agreement between molecular imaging and AVS was moderate, with positive percent agreement values ranging from 0.6 to 0.9 and negative percent agreement from 0.5 to 0.9. Cohen's κ values ranged from 0.33 to 0.93, indicating moderate-to-strong agreement beyond chance. Each tracer was assessed separately; direct comparisons between tracers were not performed, and quantitative pooling was not undertaken because of heterogeneity in tracer protocols, patient preparation, and test interpretation. Reciprocal analyses yielded similar positive percent agreement and negative percent agreement distributions, with no consistent directional bias between modalities. CONCLUSIONS: Molecular imaging shows moderate and variable agreement with AVS for localization testing in primary aldosteronism, suggesting complementary rather than competing roles. Molecular imaging may serve as an adjunct or alternative within diagnostic algorithms; however, patient outcome-based studies are still needed to define its clinical utility.
2. Adjunctive effects of apple cider vinegar on metabolic syndrome and insulin resistance in polycystic ovary syndrome patients receiving metformin: a randomized clinical trial.
In a 12-week RCT of 94 women with PCOS on metformin, adjunctive apple cider vinegar significantly increased metabolic syndrome resolution (74.5% vs 40.4%), improved insulin resistance, reduced hirsutism, and enhanced sexual function and quality of life. Findings support ACV as a low-cost adjunct to metabolic management in PCOS, pending confirmation in larger, longer trials.
Impact: Randomized evidence suggests a simple, scalable adjunct that improves metabolic and patient-reported outcomes in PCOS, addressing a major unmet need in metabolic management.
Clinical Implications: Clinicians may consider ACV as an adjunct to metformin in metabolically high-risk PCOS, with shared decision-making and monitoring; confirmatory multicenter trials and safety profiling are warranted.
Key Findings
- Metabolic syndrome resolution was higher with ACV vs placebo (74.5% vs 40.4%; p=0.001).
- Insulin resistance decreased significantly with ACV (p=0.01).
- Hirsutism improved (modified Ferriman–Gallwey; p=0.003), with gains in sexual function (FSFI; p<0.001) and quality of life (mPCOSQ; p=0.001).
- Participants met Rotterdam PCOS criteria, NCEP ATP III MetS, and HOMA-IR > 2.5; intervention dose 1500 mg/day ACV capsules for 12 weeks.
Methodological Strengths
- Randomized, placebo-controlled design with prespecified primary and secondary outcomes
- Clinically meaningful endpoints including metabolic syndrome resolution and patient-reported outcomes
Limitations
- Short duration (12 weeks) and modest sample size limit durability and generalizability
- Single-trial context without mechanistic biomarkers to explain observed effects
Future Directions: Multicenter, longer-term RCTs with dose–response testing, safety surveillance, and mechanistic profiling (gut microbiome, insulin signaling) to validate and refine ACV’s role in PCOS.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in reproductive-aged women, frequently associated with insulin resistance (IR) and metabolic syndrome (MetS). Given the limitations of conventional therapies, complementary interventions targeting metabolic pathways are needed. This randomized clinical trial investigated the adjunctive effects of apple cider vinegar (ACV) on MetS components and IR in PCOS patients receiving standard metformin treatment (1500 mg/day). In this 12-week randomized controlled trial, 94 women meeting the Rotterdam criteria for PCOS, NCEP ATP III criteria for MetS, and HOMA-IR > 2.5, were randomized 1:1 to receive either ACV capsules (1500 mg/day) or placebo. Primary outcomes were changes in IR and MetS components; secondary outcomes included serum testosterone, hirsutism (modified Ferriman-Gallwey score), sexual function (FSFI), and quality of life (mPCOSQ). The results showed resolution of MetS was significantly higher in the ACV group (74.5%) than controls (40.4%) (p = 0.001). Significant reductions in IR (p = 0.01), hirsutism (p = 0.003), and improvements in sexual function (p < 0.001) and quality of life (p = 0.001) were observed in the intervention group. These results demonstrate that ACV supplementation may offer a beneficial adjunctive strategy for improving metabolic and quality-of-life parameters in women with MetS, IR, and PCOS.Trial registration: IRCT20150905023897N7, registered on 11/12/2023.
3. Type 1 diabetes and risk of Parkinson's disease: A nationwide nested case-control study.
Using 2010–2022 Korean NHIS data, clinically established type 1 diabetes was associated with higher Parkinson’s disease risk (aOR 1.42, 95% CI 1.06–1.90), consistent regardless of microvascular complications. Findings contrast with prior Mendelian randomization signals and suggest non-genetic clinical or environmental pathways underlie risk.
Impact: This nationwide study challenges genetic inferences by demonstrating increased PD risk in clinical T1D, reframing neurodegenerative risk profiling in autoimmune endocrinology.
Clinical Implications: Heightened vigilance for parkinsonian symptoms in older adults with long-standing T1D may be warranted. Future risk models should integrate clinical factors beyond genetics.
Key Findings
- Clinically established T1DM was associated with increased PD risk (aOR 1.42, 95% CI 1.06–1.90).
- Results were directionally consistent irrespective of microvascular complication status.
- Nested case-control design using Korean NHIS (2010–2022) with age- and sex-matched controls and adjustment for vascular/metabolic comorbidities.
Methodological Strengths
- Nationwide claims database with large sampling frame and matched design
- Adjusted analyses for key vascular and metabolic comorbidities
Limitations
- Potential residual confounding and misclassification inherent to administrative data
- Lack of detailed clinical metrics (e.g., glycemic control duration, autoantibody titers) and medication effects
Future Directions: Prospective cohorts integrating glycemic trajectories, autoimmune markers, treatment exposures, and neuroimaging to elucidate mechanisms and refine risk stratification.
BACKGROUND: Recent Mendelian randomization studies have suggested a protective association of genetic liability to Type 1 diabetes mellitus (T1DM) with Parkinson's disease (PD). OBJECTIVE: To investigate the association between clinically established T1DM and PD risk in a nationwide population-based cohort. METHODS: We conducted a nested case-control study using data from the Korean National Health Insurance Service (NHIS) database (2010-2022). Patients with incident PD were matched with controls by age and sex. Conditional logistic regression was used to estimate adjusted odds ratios (aORs), controlling for vascular and metabolic comorbidities. RESULTS: T1DM was independently associated with an increased PD risk (aOR 1.42, 95% CI 1.06-1.90). The association was directionally consistent regardless of the presence of microvascular complication. CONCLUSION: In contrast to genetic studies, clinically established T1DM was associated with greater PD risk. These findings suggest that clinically established T1DM may be associated with increased PD risk through mechanisms beyond immunogenetic susceptibility, although the underlying pathways remain to be clarified.